-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Benzinga·08/07/2026 17:08:56
Listen to the news
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.